MedTrace Logo

Quality of Life Among Testicular Cancer Survivors

NCT02304575 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2017-10-17

No results posted yet for this study

Summary

Testicular Cancer is the most prevalent malignancy among men between 20 and 34 years of age, with incidence rates rising in western countries including Israel. Cure rate of testicular cancer exceeds 90% with modern treatments. Thus issues such as quality of life (QoL), coping, effects on couple relationships, cognitive function, cognitive orientation and hormonal function become increasingly important. This study aims to assess all these issues using validated, reproducible questionnaires and hormonal plasma levels, and compare them between testicular cancer survivors and controls.

Conditions

  • Testicular Neoplasms
  • Spermatic Cord Torsion
  • Varicocele
  • Testicular Hydrocele

Interventions

OTHER

Questionnaires

Questionnaires: For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires. For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory.

OTHER

Hormonal Function measurement

Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • David Margel, MD PhD · Rabin MC

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02304575 on ClinicalTrials.gov